TNF and colitis: To study the role of EVO in colitis, Shen et al (36) used murine DSS colitis model and found that treatment of EVO ameliorated DSS induced colonic symptoms, inhibited the production of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6, and restrain the activation of NLRP3 inflammasome.